CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts

$50.69

+1.10 (+2.22%)

(As of 12:58 PM ET)

Upcoming Earnings Date: Nov. 4Estimated
Actual EPS (Aug. 5): -$1.49 Missed By -$0.06
Consensus EPS (Aug. 5): -$1.43

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad InvestorPlace

Why You Should NOT Trade This Market

You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...

Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go

CRISPR Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	4	($1.98)	($1.19)	($1.59)
Q2 2024	4	($1.98)	($1.14)	($1.63)
Q3 2024	4	($1.83)	($1.18)	($1.55)
Q4 2024	4	($1.57)	($0.10)	($0.94)
FY 2024	16	($7.36)	($3.61)	($5.70)
Q1 2025	2	($1.57)	($1.29)	($1.43)
Q2 2025	2	($1.56)	($1.16)	($1.36)
Q3 2025	2	($1.42)	($1.04)	($1.23)
Q4 2025	2	($1.33)	($0.92)	($1.13)
FY 2025	8	($5.88)	($4.41)	($5.15)
Q1 2026	1	($1.24)	($1.24)	($1.24)
Q2 2026	1	($0.86)	($0.86)	($0.86)

CRSP Earnings Date and Information

CRISPR Therapeutics last announced its earnings data on August 5th, 2024. The reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.06. The business earned $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. Its quarterly revenue was down 99.3% on a year-over-year basis. CRISPR Therapeutics has generated ($2.72) earnings per share over the last year (($2.72) diluted earnings per share). Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.60) to ($4.97) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off prior year's report dates.

CRISPR Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/4/2024 (Estimated)	-	-	-	-	-	-	-
8/5/2024	Q2 2024	($1.43)	($1.49)	($0.06)	($1.49)	$12.31 million	$0.52 million
5/8/2024	Q1 2024	($1.35)	($1.43)	($0.08)	($1.43)	$25.53 million	$0.50 million
2/21/2024	Q4 2023	$0.15	$1.10	+$0.95	$1.10	$148.72 million	$201.20 million
11/6/2023	Q3 2023	($2.04)	($1.41)	+$0.63	($1.41)	$5.05 million	-
8/7/2023	Q2 2023	($2.13)	($0.98)	+$1.15	($0.98)	$1.80 million	$70.00 million
5/8/2023	Q1 2023	($1.64)	($0.67)	+$0.97	($0.67)	$24.33 million	$100.00 million
This Crypto Is Set to Explode in September (Ad) With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now.
2/21/2023	Q4 2022	($2.27)	($1.41)	+$0.86	($1.41)	$7.37 million	$6.00 million
11/1/2022	Q3 2022	($2.30)	($2.24)	+$0.06	($2.24)	$3.53 million	$0.09 million
8/8/2022	Q2 2022	($2.23)	($2.40)	($0.17)	($2.40)	$2.20 million	$0.20 million
5/9/2022	Q1 2022	($1.91)	($2.32)	($0.41)	($2.32)	$2.45 million	$0.94 million
2/14/2022	Q4 2021	($1.74)	($1.84)	($0.10)	($1.84)	$5.39 million	$12.90 million
11/3/2021	Q3 2021	($1.75)	($1.67)	+$0.08	($1.67)	$3.85 million	$0.82 million
7/29/2021	Q2 2021	$3.52	$9.44	+$5.92	$9.44	$678.05 million	$900.70 million
4/26/2021	Q1 2021	($1.47)	($1.51)	($0.04)	($1.51)	$4.99 million	$0.54 million
2/15/2021	Q4 2020	($1.27)	($1.50)	($0.23)	($1.50)	$4.69 million	$0.37 million
11/2/2020	Q3 2020	($1.18)	($1.32)	($0.14)	($1.32)	$2.22 million	$0.15 million
7/27/2020	Q2 2020	($0.95)	($1.30)	($0.35)	($1.30)	$19.77 million	$0.04 million
4/28/2020	Q1 2020	($1.05)	($1.15)	($0.10)	($1.15)	$3.04 million	$0.16 million
2/12/2020	Q4 2019	($0.68)	$0.51	+$1.19	$0.51	$39.08 million	$77.00 million
10/28/2019	Q3	($0.9480)	$2.40	+$3.3480	$2.40	$6.32 million	$211.93 million

CRISPR Therapeutics Earnings - Frequently Asked Questions

When is CRISPR Therapeutics's earnings date?: CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates. Learn more on CRSP's earnings history.
Did CRISPR Therapeutics beat their earnings estimates last quarter?: In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($1.43) by $0.06 with a reported earnings per share (EPS) of ($1.49). Learn more on analysts' earnings estimate vs. CRSP's actual earnings.
How can I listen to CRISPR Therapeutics's earnings conference call?: The conference call for CRISPR Therapeutics's latest earnings report can be listened to online. Listen to Conference Call
How can I read CRISPR Therapeutics's conference call transcript?: The conference call transcript for CRISPR Therapeutics's latest earnings report can be read online. Read Transcript
How much revenue does CRISPR Therapeutics generate each year?: CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $200 million.
How much profit does CRISPR Therapeutics generate each year?: CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$153.61 million. CRSP has generated -$2.72 earnings per share over the last four quarters.
What is CRISPR Therapeutics's EPS forecast for next year?: CRISPR Therapeutics's earnings are expected to grow from ($5.60) per share to ($4.97) per share in the next year.